Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (6): 970-976    DOI: 10.12892/ejgo4782.2019
Original Research Previous articles | Next articles
Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery
S.H. Nam1, H.R. Yang1, D. Kang2, K.O. Jung3, W.Y. Kim1, *()
1Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Cardiothoracic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
3Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Download:  PDF(431KB)  ( 179 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Objective: To analyze the survival effects of upper abdominal procedures (UAPs) in patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IIIb to IV ovarian cancer stratified by initial presence of upper abdominal disease (UAD) and UAP performance. Materials and Methods: The authors retrospectively reviewed records of patients with FIGO Stage IIIb to IV epithelial ovarian cancer confirmed by pathology between January 2007 and December 2016 from the gynecologic cancer registry of Kangbuk Samsung Hospital. Results: During the study period, 74 patients with FIGO Stage IIIb to IV epithelial ovarian cancer underwent primary cytoreductive surgery. Among them, 28 patients had no UAD and no UAPs (group 1), 30 had UAD but did not undergo complete UAPs, especially without diaphragmatic resection (group 2), and 16 had UAD and underwent complete UAP including diaphragmatic resection (group 3). Except for age, most baseline characteristics did not vary among the three groups. In group 3, diaphragm peritonectomy was the most commonly performed UAP (93.8%), followed by liver resection (6.8%) with significant differences between groups 2 and 3 (p < 0.01). Five-year OS was 77.9% in group 1, 9.5% in group 2, and 76.7% in group 3 (p < 0.01). Median PFS was 37 months in group 1, 10 months in group 2, and 25 months in group 3 (p < 0.01). Conclusions: UAPs including complete removal of diaphragmatic lesions led to better survival outcomes for advanced-stage ovarian cancer.

Key words:  Advanced-stage ovarian cancer      Upper abdominal surgery      Survival     
Published:  10 December 2019     
*Corresponding Author(s):  W.Y. KIM     E-mail:  obgykim@gmail.com

Cite this article: 

S.H. Nam, H.R. Yang, D. Kang, K.O. Jung, W.Y. Kim. Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery. European Journal of Gynaecological Oncology, 2019, 40(6): 970-976.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4782.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I6/970

[1] Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.
[2] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[3] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[4] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[5] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[6] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[7] M.E. Căpîlna, B. Szabo, J. Becsi, M. Morariu, M. Gheorghe, S.L. Kiss, B. Moldovan. Surgical complications and survival after pelvic exenteration: our experience following 60 procedures[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 171-175.
[8] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[9] S. Srdelić Mihalj, V. Čapkun, I. Kuzmić-Prusac. High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 16-22.
[10] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[11] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[12] H. Oikiri, M. Futagami, J. Watanabe, Y. Yokoyama. Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 728-733.
[13] G. Scandurra, S. Gieri, F. Marletta, B. Pecorino, S. Nicolini, G. L. Banna, G. Scibilia, P. Scollo. Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 739-743.
[14] E. Lajtman, M. Mlynček, T. Kapusta, M. Kubalová. The value of gynecological cancer follow-up: a 15-year single institutional experience[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 619-627.
[15] D.G. Attiah, I. Helenowski, T. Refaat, J.B. Strauss, S. Shahabi, J. Lurain, M. Pineda, W. Nieves-Neira, D. Matei, E.D. Donnelly. Significance of number of positive lymph nodes and size as prognostic factors of recurrence and overall survival in cervical cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 609-613.
No Suggested Reading articles found!